TScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Q1 2026 results due May 5 — TScan is set to report before the market opens on Tuesday, May 5, with analysts expecting a loss of ($0.22) EPS and $2.50 million in revenue; a conference call is scheduled for May 8 at 9:30 AM ET.
• The company beat estimates last quarter (EPS of -$0.18 vs. -$0.27 expected; revenue $2.57M vs. $2.44M) but still shows large negative margins and analysts forecast about -$1 EPS for the current and next fiscal year.
• TCRX trades around $1.31 with a market cap of ~$74.5M, carries a consensus analyst rating of "Hold" and a consensus target of $6.00, while institutional ownership is high (~82.8%) amid mixed analyst actions (Wedbush upgrade vs. recent sell ratings).

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $2.50 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 8, 2026 at 9:30 AM ET.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.09. The business had revenue of $2.57 million for the quarter, compared to analysts' expectations of $2.44 million. TScan Therapeutics had a negative return on equity of 79.36% and a negative net margin of 1,256.81%. On average, analysts expect TScan Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TScan Therapeutics Stock Performance

TCRX stock opened at $1.31 on Tuesday. The stock has a market capitalization of $74.54 million, a PE ratio of -1.31 and a beta of 1.02. TScan Therapeutics has a 12-month low of $0.88 and a 12-month high of $2.57. The company has a current ratio of 8.41, a quick ratio of 8.41 and a debt-to-equity ratio of 0.26. The stock's 50 day simple moving average is $1.09 and its 200 day simple moving average is $1.20.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on TCRX shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of TScan Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen cut TScan Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 14th. Finally, Wedbush increased their price target on TScan Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Thursday, March 5th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $6.00.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TCRX. Goldman Sachs Group Inc. lifted its holdings in shares of TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company's stock valued at $235,000 after buying an additional 9,676 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of TScan Therapeutics by 8.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company's stock valued at $417,000 after buying an additional 22,642 shares during the period. Marshall Wace LLP bought a new position in shares of TScan Therapeutics during the 2nd quarter valued at $78,000. Qube Research & Technologies Ltd bought a new position in shares of TScan Therapeutics during the 2nd quarter valued at $99,000. Finally, Jane Street Group LLC bought a new position in shares of TScan Therapeutics during the 2nd quarter valued at $309,000. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan's approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company's pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.